Mechanisms of BCR–ABL in the pathogenesis of chronic myelogenous leukaemia

[1]  C. Unger,et al.  Results from a phase I dose escalation study of PEGylated glutaminase in combination with 6-diazo-5-oxo-L-norleucine (DON) in advanced malignant solid tumors. , 2016, Journal of Clinical Oncology.

[2]  B. Druker,et al.  Oncogenes and Tumor Suppressors (795 articles) , 2004 .

[3]  A. Jin,et al.  BCR/ABL activates Rap1 and B-Raf to stimulate the MEK/Erk signaling pathway in hematopoietic cells. , 2005, Biochemical and biophysical research communications.

[4]  C. Sawyers,et al.  Hematologic and Cytogenetic Responses in Imatinib-Resistant Chronic Phase Chronic Myeloid Leukemia Patients Treated with the Dual SRC/ABL Kinase Inhibitor BMS-354825: Results from a Phase I Dose Escalation Study. , 2004 .

[5]  K. Akashi,et al.  MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. , 2004, Cancer cell.

[6]  I. Weissman,et al.  JunB Deficiency Leads to a Myeloproliferative Disorder Arising from Hematopoietic Stem Cells , 2004, Cell.

[7]  A. Gewirtz,et al.  Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR-ABL1(+) leukemia cells , 2004, Nature Medicine.

[8]  Laurie E Ailles,et al.  Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. , 2004, The New England journal of medicine.

[9]  J. Yee,et al.  Effect of Mutational Inactivation of Tyrosine Kinase Activity on BCR/ABL-Induced Abnormalities in Cell Growth and Adhesion in Human Hematopoietic Progenitors , 2004, Cancer Research.

[10]  Ping Chen,et al.  Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor , 2004, Science.

[11]  D. Motto.  ADAMTS-13, VWF, inflammation, and thrombosis , 2004 .

[12]  J. Melo,et al.  Biology of Chronic Myeloid Leukemia and Possible Therapeutic Approaches to Imatinib-Resistant Disease , 2004, International journal of hematology.

[13]  N. Speck,et al.  Core-binding factors in hematopoiesis and immune function , 2004, Oncogene.

[14]  D. Fabbro,et al.  Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia , 2004, Nature Genetics.

[15]  O. Witte,et al.  The BCR-ABL story: bench to bedside and back. , 2004, Annual review of immunology.

[16]  J. Kutok,et al.  Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease. , 2004, The Journal of clinical investigation.

[17]  T. Jacks,et al.  Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[18]  R. Ren.  Modeling the dosage effect of oncogenes in leukemogenesis , 2004, Current opinion in hematology.

[19]  A. Wells,et al.  Current Treatment Options , 2003 .

[20]  B. Druker,et al.  c-CBL is not required for leukemia induction by Bcr-Abl in mice , 2003, Oncogene.

[21]  K. Akashi,et al.  Inducible expression of BCR/ABL using human CD34 regulatory elements results in a megakaryocytic myeloproliferative syndrome. , 2003, Blood.

[22]  C. Eaves,et al.  Evidence for a positive role of SHIP in the BCR-ABL-mediated transformation of primitive murine hematopoietic cells and in human chronic myeloid leukemia. , 2003, Blood.

[23]  B. Löwenberg.  Minimal residual disease in chronic myeloid leukemia. , 2003, The New England journal of medicine.

[24]  J. Griffin,et al.  Resistance to imatinib (Glivec): update on clinical mechanisms. , 2003, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[25]  W. Pear,et al.  Localization of BCR-ABL to F-actin regulates cell adhesion but does not attenuate CML development. , 2003, Blood.

[26]  S. Itohara,et al.  Myeloproliferative stem cell disorders by deregulated Rap1 activation in SPA-1-deficient mice. , 2003, Cancer cell.

[27]  Tony Hunter,et al.  Regulation of F-actin-dependent processes by the Abl family of tyrosine kinases , 2003, Journal of Cell Science.

[28]  R. Yacobi,et al.  Autoinhibition of Bcr-Abl through Its SH3 Domain , 2003, Molecular Cell.

[29]  P. Nowell,et al.  Oligodeoxynucleotide-mediated inhibition of c-myb gene expression in autografted bone marrow: a pilot study. , 2002, Blood.

[30]  J. Licht,et al.  Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia , 2003, Nature Genetics.

[31]  B. Neel,et al.  The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling. , 2003, Trends in biochemical sciences.

[32]  P. Stork.  Does Rap1 deserve a bad Rap? , 2003, Trends in biochemical sciences.

[33]  Jan-Gowth Chang,et al.  JunB gene expression is inactivated by methylation in chronic myeloid leukemia. , 2003, Blood.

[34]  G. Superti-Furga,et al.  A Myristoyl/Phosphotyrosine Switch Regulates c-Abl , 2003, Cell.

[35]  S. Harrison,et al.  Variation on an Src-like Theme , 2003, Cell.

[36]  G. Superti-Furga,et al.  Structural Basis for the Autoinhibition of c-Abl Tyrosine Kinase , 2003, Cell.

[37]  T. Skorski,et al.  BCR/ABL regulates response to DNA damage: the role in resistance to genotoxic treatment and in genomic instability , 2002, Oncogene.

[38]  R. Ren.  The molecular mechanism of chronic myelogenous leukemia and its therapeutic implications: studies in a murine model , 2002, Oncogene.

[39]  T. Ogata,et al.  PTPN11 (protein-tyrosine phosphatase, nonreceptor-type 11) mutations in seven Japanese patients with Noonan syndrome. , 2002, The Journal of clinical endocrinology and metabolism.

[40]  Claude Preudhomme,et al.  Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. , 2002, Blood.

[41]  C. Sawyers,et al.  Molecular mechanisms of resistance to STI571 in chronic myeloid leukemia , 2002, Current opinion in hematology.

[42]  C. Sawyers,et al.  The phosphatidylinositol 3-Kinase–AKT pathway in human cancer , 2002, Nature Reviews Cancer.

[43]  M. Wasik,et al.  Complementary functions of the antiapoptotic protein A1 and serine/threonine kinase pim-1 in the BCR/ABL-mediated leukemogenesis. , 2002, Blood.

[44]  David Boettiger,et al.  BCR-ABL-induced adhesion defects are tyrosine kinase-independent. , 2002, Blood.

[45]  H. Iwasaki,et al.  Critical role for Gab2 in transformation by BCR/ABL. , 2002, Cancer cell.

[46]  D. Housman,et al.  A murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOXA9 , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[47]  M. Slovak,et al.  Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation. , 2002, Blood.

[48]  W. Pear,et al.  The coiled-coil domain and Tyr177 of bcr are required to induce a murine chronic myelogenous leukemia-like disease by bcr/abl. , 2002, Blood.

[49]  AC Eaves,et al.  Elucidating critical mechanisms of deregulated stem cell turnover in the chronic phase of chronic myeloid leukemia , 2002, Leukemia.

[50]  H. Klamová,et al.  Gene Expression Profiling in Chronic Myeloid Leukemia Patients Treated with Hydroxyurea , 2002, Leukemia & lymphoma.

[51]  R. Ren,et al.  Cooperation of BCR-ABL and AML1/MDS1/EVI1 in blocking myeloid differentiation and rapid induction of an acute myelogenous leukemia , 2001, Oncogene.

[52]  Michael A. Patton,et al.  Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome , 2001, Nature Genetics.

[53]  E. Kjeldsen,et al.  Kinetics of BCR‐ABL fusion transcript levels in chronic myeloid leukemia patients treated with STI571 measured by quantitative real‐time polymerase chain reaction , 2001, European journal of haematology.

[54]  B. Druker,et al.  Chronic myeloid leukemia: current treatment options. , 2001, Blood.

[55]  I. Mcniece,et al.  Deletion of the Src Homology 3 Domain and C-terminal Proline-rich Sequences in Bcr-Abl Prevents Abl Interactor 2 Degradation and Spontaneous Cell Migration and Impairs Leukemogenesis* , 2001, The Journal of Biological Chemistry.

[56]  P. N. Rao,et al.  Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification , 2001, Science.

[57]  D. Gershon.  From bench to bedside and back? , 2001, Nature.

[58]  C. Verfaillie,et al.  A model of human p210(bcr/ABL)-mediated chronic myelogenous leukemia by transduction of primary normal human CD34(+) cells with a BCR/ABL-containing retroviral vector. , 2001, Blood.

[59]  M. Slovak,et al.  NUP98 gene rearrangements and the clonal evolution of chronic myelogenous leukemia , 2001, Genes, chromosomes & cancer.

[60]  M. Tomasson,et al.  Interleukin 3 and granulocyte-macrophage colony-stimulating factor are not required for induction of chronic myeloid leukemia-like myeloproliferative disease in mice by BCR/ABL. , 2001, Blood.

[61]  P. Vigneri,et al.  Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR–ABL tyrosine kinase , 2001, Nature Medicine.

[62]  R. Ren,et al.  The NH2-Terminal Coiled-Coil Domain and Tyrosine 177 Play Important Roles in Induction of a Myeloproliferative Disease in Mice by Bcr-Abl , 2001, Molecular and Cellular Biology.

[63]  E. Wagner,et al.  Chronic Myeloid Leukemia with Increased Granulocyte Progenitors in Mice Lacking JunB Expression in the Myeloid Lineage , 2001, Cell.

[64]  R. Ren,et al.  Bcr-Abl has a greater intrinsic capacity than v-Abl to induce the neoplastic expansion of myeloid cells , 2000, Oncogene.

[65]  J. Melo,et al.  The molecular biology of chronic myeloid leukemia. , 2000, Blood.

[66]  R. Jaenisch,et al.  Retroviral Expression in Embryonic Stem Cells and Hematopoietic Stem Cells , 2000, Molecular and Cellular Biology.

[67]  M. Roussel,et al.  Stat5a/b contribute to interleukin 7-induced B-cell precursor expansion, but abl- and bcr/abl-induced transformation are independent of stat5. , 2000, Blood.

[68]  K. Ozato,et al.  ICSBP directs bipotential myeloid progenitor cells to differentiate into mature macrophages. , 2000, Immunity.

[69]  R. V. van Etten,et al.  The Grb2 binding site is required for the induction of chronic myeloid leukemia-like disease in mice by the Bcr/Abl tyrosine kinase. , 2000, Blood.

[70]  J. Melo,et al.  BCR-ABL tyrosine kinase activity regulates the expression of multiple genes implicated in the pathogenesis of chronic myeloid leukemia. , 2000, Cancer research.

[71]  G. Nucifora,et al.  Human AML1/MDS1/EVI1 fusion protein induces an acute myelogenous leukemia (AML) in mice: a model for human AML. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[72]  R. Ren,et al.  Expression of Interferon Consensus Sequence Binding Protein (ICSBP) Is Downregulated in Bcr-Abl-Induced Murine Chronic Myelogenous Leukemia-Like Disease, and Forced Coexpression of ICSBP Inhibits Bcr-Abl-Induced Myeloproliferative Disorder , 2000, Molecular and Cellular Biology.

[73]  H. Hirai.  The transcription factor Evi-1. , 1999, The international journal of biochemistry & cell biology.

[74]  J. Griffin,et al.  BCR/ABL Directly Inhibits Expression of SHIP, an SH2-Containing Polyinositol-5-Phosphatase Involved in the Regulation of Hematopoiesis , 1999, Molecular and Cellular Biology.

[75]  C. Eaves,et al.  Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukemia. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[76]  R. Ren,et al.  Bcr-Abl with an SH3 Deletion Retains the Ability To Induce a Myeloproliferative Disease in Mice, yet c-Abl Activated by an SH3 Deletion Induces Only Lymphoid Malignancy , 1999, Molecular and Cellular Biology.

[77]  S. Ghaffari,et al.  Growth factor independence and BCR/ABL transformation: promise and pitfalls of murine model systems and assays , 1999, Leukemia.

[78]  Z. Estrov,et al.  The biology of chronic myeloid leukemia. , 1999, The New England journal of medicine.

[79]  George Q. Daley,et al.  The P190, P210, and P230 Forms of the BCR/ABL Oncogene Induce a Similar Chronic Myeloid Leukemia–like Syndrome in Mice but Have Different Lymphoid Leukemogenic Activity , 1999, The Journal of experimental medicine.

[80]  E. Wagner,et al.  JunB is essential for mammalian placentation , 1999, The EMBO journal.

[81]  E. Buchdunger,et al.  In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor. , 1999, Journal of the National Cancer Institute.

[82]  N. Takahashi,et al.  Lineage involvement of stem cells bearing the philadelphia chromosome in chronic myeloid leukemia in the chronic phase as shown by a combination of fluorescence-activated cell sorting and fluorescence in situ hybridization. , 1998, Blood.

[83]  D. Baltimore,et al.  Essential Roles for the Abl and Arg Tyrosine Kinases in Neurulation , 1998, Neuron.

[84]  X Zhang,et al.  Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia. , 1998, Blood.

[85]  J. Melo,et al.  The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease. , 1998, Blood.

[86]  P. Wiernik,et al.  Inversion of chromosome 16 in accelerated phase of chronic myeloid leukaemia: report of a case and review of the literature , 1998, Medical oncology.

[87]  G. Krystal,et al.  Targeted disruption of SHIP leads to hemopoietic perturbations, lung pathology, and a shortened life span. , 1998, Genes & development.

[88]  J. Melo,et al.  The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. , 1997, Blood.

[89]  A. Órfão,et al.  A BCR-ABL(p190) fusion gene made by homologous recombination causes B-cell acute lymphoblastic leukemias in chimeric mice with independence of the endogenous bcr product. , 1997, Blood.

[90]  J. Waring,et al.  Immunodeficiency and Chronic Myelogenous Leukemia-like Syndrome in Mice with a Targeted Mutation of the ICSBP Gene , 1996, Cell.

[91]  T. Olson,et al.  Mature micromegakaryocytes: an unusual developmental pattern in term infants , 1996, British journal of haematology.

[92]  M. Vickers.  Estimation of the number of mutations necessary to cause chronic myeloid leukaemia from epidemiological data , 1996, British journal of haematology.

[93]  Jürg Zimmermann,et al.  Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells , 1996, Nature Medicine.

[94]  V. Kaartinen,et al.  BCR/ABL P210 and P190 cause distinct leukemia in transgenic mice. , 1995, Blood.

[95]  G. Huez,et al.  Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals. , 1995, Blood.

[96]  O. Witte,et al.  Alternative signals to RAS for hematopoietic transformation by the BCR-ABL oncogene , 1995, Cell.

[97]  Y. Yazaki,et al.  Expression of p210bcr/abl by metallothionein promoter induced T-cell leukemia in transgenic mice. , 1995, Blood.

[98]  V. Kaartinen,et al.  Increased neutrophil respiratory burst in bcr-null mutants , 1995, Cell.

[99]  R. Hawley.  High‐Titer Retroviral Vectors for Efficient Transduction of Functional Genes into Murine Hematopoietic Stem Cells a , 1994, Annals of the New York Academy of Sciences.

[100]  T Pawson,et al.  Bcr‐Abl oncoproteins bind directly to activators of the Ras signalling pathway. , 1994, The EMBO journal.

[101]  J. Wang,et al.  A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins , 1993, Molecular and cellular biology.

[102]  Nanxin Li,et al.  BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein , 1993, Cell.

[103]  J. Wang,et al.  An actin‐binding function contributes to transformation by the Bcr‐Abl oncoprotein of Philadelphia chromosome‐positive human leukemias. , 1993, The EMBO journal.

[104]  M. Greaves,et al.  Restricted oncogenicity of BCR/ABL p190 in transgenic mice. , 1992, Cancer research.

[105]  D. Kioussis,et al.  Humanbcr-abl gene has a lethal effect on embryogenesis , 1991, Transgenic Research.

[106]  S. Goff,et al.  Mice homozygous for the abl m1 mutation show poor viability and depletion of selected B and T cell populations , 1991, Cell.

[107]  R. Bronson,et al.  Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogene , 1991, Cell.

[108]  N. Rosenberg,et al.  Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[109]  A. Elefanty,et al.  bcr‐abl, the hallmark of chronic myeloid leukaemia in man, induces multiple haemopoietic neoplasms in mice. , 1990, The EMBO journal.

[110]  G. Jenster,et al.  Acute leukaemia in bcr/abl transgenic mice , 1990, Nature.

[111]  G. Daley,et al.  Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. , 1990, Science.

[112]  J. L. Bos,et al.  ras oncogenes in human cancer: a review. , 1989, Cancer research.

[113]  J U Gutterman,et al.  The molecular genetics of Philadelphia chromosome-positive leukemias. , 1988, The New England journal of medicine.

[114]  D. Baltimore,et al.  Sequences of the A-MuLV protein needed for fibroblast and lymphoid cell transformation , 1983, Cell.

[115]  B. Göttgens,et al.  Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis. , 2005, Blood.

[116]  A. Koleske,et al.  How do Abl family kinases regulate cell shape and movement? , 2004, Trends in cell biology.

[117]  J. Goldman,et al.  Chronic myeloid leukemia-still a few questions. , 2004, Experimental hematology.

[118]  T. Holyoake,et al.  Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. , 2002, Blood.

[119]  R. V. van Etten,et al.  The src homology 2 domain of Bcr/Abl is required for efficient induction of chronic myeloid leukemia-like disease in mice but not for lymphoid leukemogenesis or activation of phosphatidylinositol 3-kinase. , 2001, Blood.

[120]  W. Pear,et al.  The SH2 domain of bcr-Abl is not required to induce a murine myeloproliferative disease; however, SH2 signaling influences disease latency and phenotype. , 2001, Blood.

[121]  D. Tenen,et al.  Reversibility of acute B-cell leukaemia induced by BCR–ABL1 , 2000, Nature Genetics.

[122]  J. Waring,et al.  Lack of interferon consensus sequence binding protein (ICSBP) transcripts in human myeloid leukemias. , 1998, Blood.

[123]  J. Aster,et al.  Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. , 1998, Blood.

[124]  J. Ihle,et al.  Insertional mutagenesis and the transformation of hematopoietic stem cells. , 1993, Hematologic pathology.

[125]  Robert C. Wolpert,et al.  A Review of the , 1985 .

[126]  L. Teodori,et al.  Report of a Case and Review of the Literature , 1981 .

[127]  Willard A. Burns,et al.  Report of a Case and Review of the Literature , 2017 .